Abioclav

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abioclav

Abioclav is a brand-name prescription antibiotic medication that is a combination of two active ingredients: amoxicillin and clavulanate potassium (also known as clavulanic acid). This combination is classified as a penicillin-class antibacterial and a beta-lactamase inhibitor.

Mechanism of Action

Abioclav works to treat a wide range of bacterial infections. Amoxicillin is an antibiotic that belongs to the penicillin family. It works by interfering with the bacteria's ability to build and maintain its cell wall, which ultimately leads to the death of the bacteria.

However, some bacteria have developed resistance to amoxicillin by producing an enzyme called beta-lactamase, which degrades the antibiotic. Clavulanate potassium is added to the formulation to counteract this resistance. Clavulanate potassium is a beta-lactamase inhibitor that binds to and deactivates the enzyme, protecting amoxicillin from destruction. This synergistic action allows Abioclav to be effective against bacteria that would otherwise be resistant to amoxicillin alone.

Approved Uses

Healthcare providers prescribe Abioclav to treat infections caused by susceptible bacteria, including common infections of the:

  • Lower respiratory tract, such as pneumonia
  • Middle ear (acute otitis media)
  • Sinuses (acute bacterial sinusitis)
  • Skin and soft tissue
  • Urinary tract.

What side effects are possible with Abioclav?

Possible Side Effects and Safety Information

The safety profile of Abioclav (amoxicillin and clavulanate potassium) is officially categorized by the frequency and the System-Organ-Class (SOC) affected, based on regulatory documentation. Adverse reactions are grouped into categories such as Very Common, Common, Uncommon, and Rare.

The most frequently reported side effect is diarrhea, classified as Very Common. Other Common reactions involve the Gastrointestinal system, including nausea and vomiting, and Infections and Infestations, such as mucocutaneous candidosis.

Officially Documented Safety Concerns

Adverse events involving the Hepatobiliary Disorders and Immune System Disorders are of clinical significance. Hepatitis and cholestatic jaundice are documented, and their signs may not become apparent until several weeks after treatment has ceased. Hepatic events are reported predominantly in older adults and males.

Serious adverse reactions listed in regulatory sources include potentially fatal hypersensitivity reactions (e.g., anaphylaxis and angioneurotic oedema) and Severe Cutaneous Adverse Reactions (SCAR), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Antibiotic-associated colitis and rare events like Kounis syndrome are also documented.

Safety notes include restrictions for specific populations. The medicine is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with its previous use. Caution is required in patients with impaired renal function, as this may increase the risk of convulsions. Periodic assessment of organ function is advised during prolonged therapy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Abioclav overdose primarily documents two classes of manifestation: common gastrointestinal effects and rare but serious systemic outcomes. Documented overdose presentations often involve vomiting, diarrhea, and abdominal pain, which may lead to fluid and electrolyte imbalance. Other reported manifestations include drowsiness, hyperactivity, and skin rash.

Serious or life-threatening outcomes center on the Central Nervous System (CNS) and renal system. Severe overdose is associated with the risk of convulsions or seizures, particularly in individuals with pre-existing impaired renal function. The amoxicillin component can also cause crystalluria leading to acute renal failure in rare cases.

Official guidance mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if the affected person has experienced a seizure, has trouble breathing, or cannot be awakened. Treatment involves symptomatic and supportive measures, with monitoring of renal function and fluid status being essential. Regulatory information confirms that no specific antidote is known, but hemodialysis is an established procedure to remove the active components from the circulation in severe cases. Adequate fluid intake is advised to mitigate the risk of crystalluria.

Therapeutic Uses of Abioclav

Abioclav is used in situations involving certain distressing symptoms associated with bacterial infections across key therapeutic domains. The medication provides supportive relief relevant in situations associated with more challenging bacterial conditions, helping to address conditions marked by heightened physiological stress. It is applied in addressing conditions that include infections of the lower respiratory tract, middle ear (acute otitis media), sinuses (acute bacterial sinusitis), skin and soft tissue, and the urinary tract.

The clinical relevance is its use in managing symptoms in conditions characterized by periods of heightened symptoms. It contributes to easing the overall symptom load in acute episodes, which supports general well-being during symptomatic phases. It is applied in clinical settings that involve acute or unstable symptom patterns, such as conditions involving inflammatory or irritative processes or conditions involving episodic or fluctuating manifestations.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Abioclav (amoxicillin/clavulanic acid) is an antibiotic prescribed for susceptible bacterial infections in adults and children. However, official regulatory documents define strict limitations on who can use this medicine.

Contraindications (Must Not Use)

  • Allergy and Hypersensitivity: The medicine is strictly contraindicated in patients with a known history of hypersensitivity to the active ingredients (amoxicillin or clavulanic acid), to any penicillin antibiotic, or to other beta-lactam agents (e.g., cephalosporins) if the reaction was severe (e.g., anaphylaxis).
  • Prior Liver Damage: Use is contraindicated in patients with a history of jaundice or hepatic dysfunction associated with previous use of amoxicillin/clavulanic acid.

Restricted or Not Recommended Populations

  • Infectious Mononucleosis: The use of Abioclav should be avoided in patients with suspected or confirmed infectious mononucleosis due to the high risk of developing a generalized skin rash.
  • Renal Impairment: Patients with severe kidney problems (creatinine clearance < 30 ml/min) require careful dose adjustment or the use of alternative formulations. Certain extended-release tablets may be contraindicated in severe renal disease.
  • Hepatic Impairment: Patients with existing liver problems (not linked to prior Abioclav use) should use the drug with caution, requiring regular monitoring of liver function.
  • Age Limits: Specific tablet strengths may be not recommended for children weighing less than 40 kg, for whom pediatric-specific formulations are available.

What should I know about interactions with other medicines?

The official regulatory profile for Abioclav (amoxicillin and clavulanate potassium) documents several clinically significant interactions with other medicines and products.

Co-administration with Probenecid is not recommended due to a pharmacokinetic interaction; this substance decreases the renal tubular secretion of amoxicillin, resulting in increased and prolonged concentrations of the antibiotic in the blood. When combined with oral anticoagulants, the drug may cause a pharmacodynamic interaction that increases the prolongation of prothrombin time. Caution is also warranted with Allopurinol, as regulatory data shows co-administration increases the incidence of skin rashes. Furthermore, Abioclav may reduce the efficacy of combined oral contraceptives by affecting intestinal flora and subsequent estrogen reabsorption.

Regarding food, a mandatory timing rule is established: the medicine must be taken at the start of a meal. This requirement is due to enhanced absorption of the clavulanate component when administered with food.

The regulatory documentation notes specific interaction-related risks for patient groups. Hepatic function should be monitored in patients with hepatic impairment. Additionally, avoidance is recommended for patients with infectious mononucleosis because of a documented heightened risk of skin rash. Abioclav is formally contraindicated in any patient with a prior history of cholestatic jaundice or hepatic dysfunction linked to its previous use.

Mechanism of Action

Blocking the Bacterial Cell Wall Assembly Line

The core mechanism involves amoxicillin targeting bacterial Penicillin-Binding Proteins (PBPs), which are essential enzymes for constructing the structural peptidoglycan layer of the cell wall. By irreversibly inhibiting these proteins, amoxicillin halts the final cross-linking step of the peptidoglycan structure, leading to structural failure, osmotic instability, and the subsequent lysis (destruction) of the bacterial cell.


Neutralizing Enzymatic Resistance Mechanisms

The mechanism is fortified by clavulanate potassium, which acts as a suicide inhibitor against bacterial beta-Lactamase enzymes. These enzymes typically hydrolyze the beta-lactam ring of amoxicillin, mediating bacterial resistance. Clavulanate neutralizes them by binding irreversibly to their active site, thereby preventing the hydrolysis of amoxicillin. This allows amoxicillin to reach its structural targets unhindered.


The Synergistic Bactericidal Cascade

This combination initiates a synergistic cascade where the resistance-nullifying mechanism (clavulanate) maintains the integrity of the cell-destruction mechanism (amoxicillin). The resulting physiological effect is the bactericidal action against susceptible organisms, achieved by simultaneously blocking the structural cross-linking and neutralizing the beta-Lactamase resistance enzymes.

Dosage and Administration Information

How Abioclav is Used: Administration Guidelines

Abioclav (amoxicillin and clavulanate potassium) is a prescription antibiotic that must be used strictly according to the provided instructions. This section outlines the guidelines for administration and dosing.


Administration Scope

Instruction Entity Guideline
Route of Administration Exclusively oral (by mouth).
Timing in Relation to Meals Must be taken at the start of a meal to enhance absorption and minimize gastrointestinal intolerance.
Dosing Schedule & Duration Dosed either every 8 hours (TID) or every 12 hours (BID), depending on the strength. The course of therapy typically lasts 5 to 14 days.

Key Procedural Instructions

  • Dose Frequency: The 875 mg/125 mg tablet strength is generally dosed every 12 hours, while the 500 mg/125 mg strength is generally dosed every 8 hours.
  • Special Handling: Extended-release tablets must be swallowed whole and must not be crushed, chewed, or cut, as this would compromise the release mechanism. Oral suspensions must be reconstituted with water and shaken well before each dose.
  • Renal Impairment: Dose adjustments are mandatory for patients with impaired kidney function (CrCl < 30 mL/min). The 875 mg/125 mg tablet strength is specifically not recommended in this population due to the fixed amoxicillin to clavulanate ratio.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless the next dose is due shortly, in which case the missed dose should be skipped. Two doses must not be taken simultaneously.

These instructions define the protocol for using Abioclav, ensuring proper drug delivery and adherence to the dosing regimen.

Recent Clinical Evidence

Evidence for Acute Respiratory and Ear Infections

This section describes the clinical research, primarily short-term studies and systematic reviews, that has explored the combination drug in the context of conditions associated with acute or disruptive episodes in the ear and upper respiratory tract. This evidence was studied for how outcomes related to physical discomfort and systemic imbalance change over time during the immediate treatment period.

Clinical Trials for Acute Otitis Media

Research on acute otitis media, or middle ear infection, has mainly focused on pediatric populations, specifically infants and children. These studies primarily involved randomized controlled trials (RCTs) where the drug was compared to amoxicillin alone or a placebo. The outcomes that research examined included clinical response (measured by the evolution of key symptoms like fever and ear pain) and the need for additional therapy at specific follow-up appointments. Data show patterns related to how clinical outcomes evolved in environments where bacteria resistant to amoxicillin may be a factor. What remains uncertain is a full understanding of the long-term effects after the initial treatment has ended, as follow-up durations were limited in most trials.

Studies in Lower Respiratory Tract Infections

Research for conditions associated with acute or disruptive episodes like community-acquired pneumonia (CAP) was primarily conducted in adult populations, including older adults, using controlled clinical trials. These studies monitored outcomes reflecting daily functioning and overall clinical response (measured by the evolution of signs and symptoms), often comparing the drug to other common antibiotic options. Findings describe patterns observed regarding the proportion of patients who met the criteria for clinical outcome measurement by the post-treatment assessment visit. Evidence is limited in terms of large, head-to-head randomized studies that specifically compare the combination drug against amoxicillin alone for all types of CAP.

Unanswered Questions and Research Gaps

The available evidence base, while extensive for certain acute conditions, may still leave several areas uncertain. Evidence quality varies across studies, leading to mixed findings regarding the specific research questions that were explored. Data are still emerging regarding specific subgroups of patients, and long-term effects are not fully established for any of the indications.

Key Studies & References

  1. Effectiveness of amoxicillin and amoxicillin-clavulanate for the treatment of community-acquired pneumonia in adults and children: systematic review and meta-analysis
  2. Otitis media (acute): antimicrobial prescribing - NICE guideline (NG91)

Frequently Asked Questions (FAQ)

Common questions about Abioclav (FAQ)


Q: How quickly does Abioclav usually start to work?

Official information indicates that the drug begins working against bacteria within a few hours of administration. However, official documents state that patients may not observe a clinical improvement in symptoms until after 24 to 72 hours, which is typically one to three days.


Q: What happens if I stop taking Abioclav early?

Official documents describe that ending the course of therapy earlier than prescribed is associated with the possibility of the original infection returning. This action is also noted to increase the likelihood of the remaining bacteria developing antibiotic resistance.


Q: What are the main reasons people stop taking Abioclav?

Official drug safety documents report that the most frequently experienced adverse reactions are diarrhea and nausea. These gastrointestinal events are often cited in studies as reasons why some patients discontinue use of the medicine.


Q: Does Abioclav make you feel tired or drowsy?

Official product information does not list general tiredness or drowsiness as a common or very common side effect. However, uncommon side effects such as dizziness and headache, and rare effects like confusion or agitation, have been reported in regulatory sources.


Q: Can Abioclav affect my sleep pattern?

Official documents note that insomnia, or difficulty sleeping, is listed among the possible central nervous system side effects that have been reported by patients using this medicine.


Q: Can Abioclav affect my mood or cause anxiety?

Regulatory safety documents indicate that effects on the central nervous system have been reported. These effects can include changes such as anxiety, agitation, confusion, and other behavioral changes.


Q: Can Abioclav make my skin more sensitive to the sun?

The official product label does not commonly list sensitivity to sunlight (photosensitivity) as a side effect. It does document the potential for rare, severe skin reactions, but these are generally not related to sun exposure.


Q: What does 'contraindicated' mean for Abioclav?

The term 'contraindicated' in official drug documents refers to conditions where the medicine is not permitted for use under specific health circumstances. Examples include a known history of penicillin allergy or previous liver damage linked to the use of amoxicillin and clavulanate.


Q: Can Abioclav affect the results of blood tests?

Official safety information states that this drug may interfere with some laboratory procedures. This interference can sometimes lead to abnormal results in certain blood tests, such as those monitoring liver enzymes or blood cell counts.


Q: Does Abioclav interfere with driving or operating machinery?

Regulatory documents state that the drug can potentially cause side effects, such as dizziness or convulsions. If these effects occur, they may temporarily make a person unfit to perform tasks that require alertness, such as driving or operating machinery.


Q: Is there any research on Abioclav's use in pregnant women?

The US FDA classifies this drug in Pregnancy Category B, meaning animal reproduction studies have not demonstrated a risk to the fetus. However, official labeling states that there are no adequate, controlled studies in pregnant women to fully confirm safety.


Q: What is the risk of using Abioclav while breastfeeding?

Studies indicate that the amoxicillin component is excreted into breast milk in small amounts. Official documents state that the manufacturer recommends caution when the medicine is used by a woman who is nursing.


Q: Why does Abioclav have a Black Box Warning (if applicable)?

Official product information states that Abioclav does not carry an FDA Black Box Warning. The label does contain strong warnings regarding serious potential risks, including severe allergic reactions and liver dysfunction.


Q: How long does the effect of one dose of Abioclav last in the body?

Pharmacokinetic data from official sources indicate that the amoxicillin component of the drug has a short half-life, meaning it is rapidly eliminated from the body. Because of this rapid elimination, the prescribing schedule is designed to ensure the drug is administered at regular intervals to maintain continuous active levels.


Q: Can Abioclav cause yeast infections in men?

Regulatory documents report that mucocutaneous candidiasis, commonly referred to as a thrush or yeast infection, is a common side effect of the medicine. This is listed as a general side effect and is not differentiated by gender in the official label.


Q: Is Abioclav safe for use if I am elderly?

Official documents note that the medicine has been associated with a higher incidence of hepatic events (liver problems) in older adults and males. Due to the potential for reduced kidney function, the official labeling describes that older patients may be subject to careful monitoring or dose adjustments.


Q: Can children or teenagers take Abioclav?

The medicine is approved for use in pediatric patients by regulatory authorities. The official label notes that specific pediatric formulations are available, and certain higher-strength tablets are typically only recommended for patients weighing 40 kilograms or more.


Q: What are the most common side effects people report online for Abioclav?

Official regulatory labels list diarrhea, nausea, and vomiting as Very Common or Common adverse effects. These official designations align with the most frequently reported side effects often discussed in patient communities.


Q: Does Abioclav cause any long-term health problems?

Official safety information states that hepatic dysfunction (liver problems) is a documented risk. The signs of this adverse event may not become apparent until several weeks after treatment has ceased, which is a recognized delayed effect.

How should Abioclav be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Amoxicillin and Clavulanate Potassium

Storage & disposal scope Labeled requirements (Regulatory Source Basis)
Labeled storage temperature requirements Dry forms: Controlled room temperature (20 C to 25 C). Reconstituted suspension: Must be refrigerated (2 C to 8 C).
Light/moisture protection requirements Store in the original container, protected from moisture and excess heat.
Stability after reconstitution The reconstituted suspension must be discarded after 10 days [Source: DailyMed, Drugs.com].
Handling requirements The reconstituted suspension must not be frozen. Keep the container tightly closed.
Disposal instructions Discard any unused medication after the stability period. Dispose of contents/container in accordance with local, regional, and national regulations.
Child-protection storage Must be stored out of the reach of children.

Connection to the overall storage/disposal profile: Regulatory documents define distinct, mandatory storage conditions based on the product's form. Dry tablets and powder require controlled room temperature storage with moisture protection, while the liquid suspension requires cold storage (refrigeration) to maintain chemical stability, with an explicit prohibition against freezing. The stability window is strictly limited, requiring the liquid to be discarded after 10 days, and all final disposal must adhere to official local waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Abioclav found in:

A-Z Index: